Details of the Drug Combinations

General Information of This Drug (ID: DM5H0R9)

• Drug Name: Enzastaurin (DM5H0R9)
• Synonyms: LY317615; LE-0014; LY317615, Enzastaurin; 3-(1-methyl-1H-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione

Indication

Diffuse large B-cell lymphoma; ICD 11: 2A81; Status: Phase 3 [1]; Non-hodgkin lymphoma; ICD 11: 2B33.5; Status: Phase 3 [2]; Glioblastoma multiforme; ICD 11: 2A00.0; Status: Phase 2 [2]; Central nervous system disease; ICD 11: 8A04-8D87; Status: Phase 1 [2]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

9 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Enzastaurin + Gemcitabine	DC261WU	Gemcitabine	Pancreatic Neoplasm	[3]
Enzastaurin + Pemetrexed	DC5PC5N	Pemetrexed	Non-small Cell Lung Cancer	[4]
Enzastaurin + Capecitabine	DC67GEC	Capecitabine	Breast Cancer	[5]
Enzastaurin + Temozolomide	DC9LI77	Temozolomide	Glioblastoma	[6]
Enzastaurin + Bicalutamide	DC9OFZ0	Bicalutamide	Prostate Cancer	[7]
Enzastaurin + Warfarin	DCCNBQT	Warfarin	Solid Tumor	[8]
Enzastaurin + Sunitinib	DCER4MC	Sunitinib	Metastatic Renal Cell Carcinoma	[9]
Enzastaurin + Erlotinib	DCNTHLC	Erlotinib	Non-Small Cell Lung Cancer	[10]
Fulvestrant + Enzastaurin	DCDIBHO	Fulvestrant	Breast Cancer	[11]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5693).
• [3] ClinicalTrials.gov (NCT00267020) Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer
• [4] ClinicalTrials.gov (NCT00530621) Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer
• [5] ClinicalTrials.gov (NCT00437294) Enzastaurin in Combination of Capecitabine to Treat Breast Cancer
• [6] ClinicalTrials.gov (NCT00402116) Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
• [7] ClinicalTrials.gov (NCT00685633) Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer
• [8] ClinicalTrials.gov (NCT01388335) A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin
• [9] ClinicalTrials.gov (NCT00709995) A Study for Participants With Metastatic Renal Cell Carcinoma
• [10] ClinicalTrials.gov (NCT00452413) A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
• [11] ClinicalTrials.gov (NCT00451555) Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer